diabetes products

Quote

Anonymous

Guest
i have submitted my background/consumer check paper work and am awaiting an offer which i am 99% sure will come due to candid conversations with HR and interviewing panel. i am now beginning in depth studying products which i will be selling...humalog, 75/25, 50/50 and byetta and also prob BI's Dpp4 linagliptin once approved. but the reality i am seeing is these are all me too products and seem to be in many ways inferior to novonordisk's portfolio of insulins and victoza, and also januvia. question is does anyone have any insight on how lilly's products are competitively positioned?
 






byetta is less effective than victoza and requires bid injection, plus increased risk of pancreatitis and more severe side effects. docs are choosing victoza over byetta and we can't get new approval for once week dosing...
 






Humalog and the variations are no less efficacious than NN's portfolio...it's the mere fact that NN only markets diabetes products. Linagliptin's only advantage over other DPP4's is the fact that there may be no need for repetitive renal testing because of the way that it is metabolised. Byetta may have blown its proverbial wad as far as innovation goes. There are some docs that absolutely love it as well as pats and its successful history will help sustain sales..maybe not grow alot but at least sustain. You must remember that NN's products are "me too" products more so than Humalogs portfolio. The pipeline here is pretty significant as far as diabetes products..there is a substantial BI co-promote product in the near future (2012 or 13) that will be a MAJOR mover. Having said that, seeing as we are FDE candidates, we may not be here for it...but there are going to some major improvements in DM care in the not see distant future. There are way too many players entering the DM market (i.e. BI et al) for there not to be some pretty good products coming to market...especially with the monster that DM is becoming. I understand your concerns but be comforted in knowing that you are selling (or will be) some top notch products.
 






Anonymous said:
i have submitted my background/consumer check paper work and am awaiting an offer which i am 99% sure will come due to candid conversations with HR and interviewing panel. i am now beginning in depth studying products which i will be selling...humalog, 75/25, 50/50 and byetta and also prob BI's Dpp4 linagliptin once approved. but the reality i am seeing is these are all me too products and seem to be in many ways inferior to novonordisk's portfolio of insulins and victoza, and also januvia. question is does anyone have any insight on how lilly's products are competitively positioned?
Click to expand...

You don't need to do a lot more "in-depth study" to discover how Lilly's diabetes products are competitively positioned. Lilly's diabetes products are all old and do not compare at all with the innovative competitors and their innovative products. Remember the old business school case studies?.....the ones that talk about companies that still tried to be successful at selling horse drawn carriages as the automobile market began to take off. In terms of diabetes products, Lilly is still trying to be successful selling the "horse drawn carriage" products in the diabetes market, and hoping to compete against new and innovative products. It is so sad because at one time, Lilly was the innovator....and virtually owned the diabetes market. It was all pissed away by the likes of Taurel and others.

That's what you are headed for if you start selling for Lilly diabetes.
 












Anonymous said:
Lilly is not perfect by any means, but we are not the "me too" company. Uh, that would be Novo.
Click to expand...

You are certainly right about that! In order to be a "me too" company in the diabetes area, Lilly would have to come up with a workable pen or an answer to Lantus. Maybe Lilly is working on a new insulin called "beefalog" or "porkalog".....that's how behind the times they are in discovering innovative products for one of the fastest growing markets in the entire country. Lilly continues to amaze me with their stupidity in that market, and I feel sorry for the sales reps who have to represent Lilly...a has been in diabetes care.
 


















Anonymous said:
You are certainly right about that! In order to be a "me too" company in the diabetes area, Lilly would have to come up with a workable pen or an answer to Lantus. Maybe Lilly is working on a new insulin called "beefalog" or "porkalog".....that's how behind the times they are in discovering innovative products for one of the fastest growing markets in the entire country. Lilly continues to amaze me with their stupidity in that market, and I feel sorry for the sales reps who have to represent Lilly...a has been in diabetes care.
Click to expand...

When a doctor asks a Lilly diabetes rep "What's new?"......does the rep say "Doctor, let me show you some new information on Humalog?"
 






When the doctor asks the Lilly diabetes rep "What's new?", the answer might be "Well, we were going to have Bydureon, but the FDA said no. Let me show you the latest study (2000) on Humalog." And the doctor might say, "It looks like Lilly got skunked again by the innovative research people at Novo!"

It must be tough being a Lilly diabetes rep these days.
 






Top Bottom
Back
Quote